68 results about "Hepg2 cells" patented technology

The application belongs to the technical field of medicine preparation, and particularly relates to a magnetic layered double hydroxide, a targeted drug-loaded nano preparation, a preparation method and application of a tumor-targeted drug-loaded nano preparation. The preparation method of the magnetic layered double hydroxide provided by the application can prepare Fe3O4 nanoparticles with small particle size, and further prepare the magnetic layered double hydroxide which can be used as a water-soluble drug carrier. The magnetic layered double hydroxide is used for preparing the targeted drug-loaded nano preparation and the tumor-targeted drug-loaded nano preparation, and can be used for delivering water-soluble drugs such as 5-fluorouracil. The tumor-targeted drug-loaded nano preparation has good dispersity and can be actively targeted to HepG2 cells with high FR expression, has a good inhibitory effect on liver cancer cells, and is expected to provide a potential new treatment system for magnetic chemotherapy.

The invention relates to phloroglucinol meroterpenoid compounds Hypercm A and B and a preparation method and application thereof, and belongs to the field of medical chemistry, the phloroglucinol meroterpenoid compounds Hypercm A and B are extracted and separated from Hypericum acalyx branches and leaves for the first time, and the structural formulas of the phloroglucinol meroterpenoid compounds Hypercm A and B are formula (I) and formula (II). The phloroglucinol meroterpenoids Hypericmoses A and B and pharmaceutically acceptable auxiliary materials have the advantages that the phloroglucinol meroterpenoids Hypericmoses A and B have obvious inhibition effects on HepG2 cells induced by oleic acid (OA) and have application potential in the field of lipid-lowering medicines, and the invention further relates to a pharmaceutical composition which comprises the phloroglucinol meroterpenoids Hypericmoses A and B and pharmaceutically acceptable auxiliary materials and has lipid-lowering effects.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

This invention discloses a eucalyptane-type sesquiterpene dimer compound, its preparation method, and its applications, belonging to the field of pharmaceutical preparation technology. The six eucalyptane-type sesquiterpene dimers (compounds 1-6) disclosed in this invention are novel compounds with defined stereostructures and optically pure composition, exhibiting varying degrees of cytotoxic activity against HepG2, Hep3B, and Huh7 cells. Using sorafenib as a positive control, compounds 1, 5, and 6 showed stronger cytotoxic activity against HepG2 cells than the positive control sorafenib, compound 5 exhibited the strongest cytotoxic activity against Hep3B cells, and compounds 1, 4, 5, and 6 showed stronger cytotoxic activity against Huh7 cells than the positive control sorafenib. Therefore, compounds 1-6 disclosed in this invention have the potential to be developed into anti-hepatocellular carcinoma drugs, showing promising application prospects, and also provide important theoretical support for the further development of Atractylodes macrocephala medicinal plant resources.

The invention belongs to the technical field of biology, and discloses application of DVM nanoparticles in preparation of products for treating and / or preventing alcoholic liver diseases, the DVM nanoparticles contain gallic acid derivatives VM and dihydromyricetin; the mass ratio of the gallic acid derivative VM to the dihydromyricetin is 1: 3; in alcohol-induced HepG2 cells, the DVM nanoparticles can better reduce apoptosis of hepatocytes and generation of ROS, improve ADH activity, reduce AST and ALT activities in the cells and improve the hangover alleviating ability in mice, and have a more excellent liver protection effect compared with gallic acid and a positive drug silibinin.

The invention discloses an extraction and purification method and application of malus toringoides leaf and leaf tea polyphenol, and belongs to the field of separation and application of natural plant products. The method comprises the following steps: mixing malus toringoides fruit and leaf dry tea powder with ethanol according to a set material-to-liquid ratio, and carrying out ultrasonic treatment on the mixed solution to obtain a malus toringoides fruit and leaf tea polyphenol crude extract; adding the malus toringoides leaf and leaf polyphenol crude extract into a chromatographic column filled with macroporous resin, and performing elution adsorption with an ethanol solution after adsorption equilibrium is achieved; and recovering the eluent, and freeze-drying to obtain the purified malus toringoides leaf and leaf tea polyphenol extract. The malus toringoides leaf and leaf tea polyphenol extract obtained by the invention has strong free radical scavenging capacity, can effectively inhibit active oxygen of HepG2 cells, and can be used for researching, developing and preparing antioxidant functional foods and medicines.

The application discloses a Salicornia polysaccharide as well as a preparation method and application thereof. The Salicornia polysaccharide is composed of 11 kinds of monosaccharides, wherein arabinose (24.96%), galactose (30.39%) and galacturonic acid (23.20%) are main monosaccharides of the polysaccharide, and the relative molecular weight is 3.24*10 4 Da. The Salicornia polysaccharide has a very special surface morphological structure, and presents a regular sawtooth distribution. The anti-tumor activity of the Salicornia polysaccharide is researched, and it is found that the polysaccharide can inhibit the growth of HepG2 cells, and the molecular mechanism of the anti-tumor activity is that the polysaccharide can induce the apoptosis of HepG2 cells. The Salicornia polysaccharide has significant anti-tumor activity, can be used as a candidate drug for developing an anti-tumor drug, and has a wide development prospect.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of the FER1L6 gene in the prevention and treatment of diabetes. In this application, the expression of GLUT4 is increased by inhibiting the expression of FER1L6, thereby improving the related physiological metabolism in diabetic organisms. This physiological metabolism includes glucose uptake, lipid metabolism, and oxidative stress damage. Experimental results show that FER1L6 is highly expressed in type 2 diabetic mice and insulin-resistant HepG2 cells; reducing FER1L6 expression significantly increases GLUT4 expression, ultimately improving lipid metabolism and oxidative stress damage in diabetic mice, while also enhancing cellular glucose uptake. Therefore, it can be concluded that FER1L6 is a good regulatory target for the prevention and treatment of type 2 diabetes based on the GLUT4 pathway. Based on this target, new technical approaches can be provided for the prevention and control of type 2 diabetes.

The invention belongs to the field of functional food and biomedicine, and relates to a method for preparing polysaccharide modified selenium nanoparticles. A chitosan oligosaccharide-sodium alginate compound is used as a stabilizer, Na2SeO3 is used as a selenium source, Vc is used as a reducing agent, novel selenium nano-particles (COS-SA-SeNPs) are prepared through a chemical synthesis method, the stability of the particles is improved, and the optimal preparation method is determined by taking the particle size as an index. Investigating the physical and chemical stability; the interaction mode of the COS-SA-SeNPs is defined; the influence of the COS-SA-SeNPs on HepG2 cell growth is further researched, and an action mechanism of inducing HepG2 cell ferroptosis by the COS-SA-SeNPs is disclosed. According to the invention, the stability of SeNPs is improved by preparing COS-SA-SeNPs, the anti-hepatoma activity of the SeNPs is proved, and reference is provided for further development and utilization of the SeNPs in the fields of functional foods with anti-hepatoma effects, foods for special medicine, foods for special diets and the like.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The application discloses a white tea composition and an extraction process and application thereof, and the composition is prepared from white tea, roxburgh rose, honeysuckle, mulberry and ginkgo leaves, wherein the white tea, roxburgh rose and honeysuckle are each 5-15 parts, and the ginkgo leaves are 2-8 parts; the extraction process is that the five medicinal materials are weighed according to the proportion, 45%-75% ethanol is added, microwave-assisted extraction is adopted, and the extract is collected, and the white tea composition can significantly inhibit H2O2-induced HepG2 cell oxidative damage, restore cell viability, effectively reduce intracellular ROS level, improve mitochondrial membrane potential, significantly enhance endogenous antioxidant enzyme activities such as SOD, GPX and GSH, and reduce the content of MDA, thereby providing theoretical support for application research and product development of the composition in the fields of health food, medicine and cosmetics, and embodying good application potential of the natural antioxidant. The optimized composition extraction process is stable and feasible, and the comprehensive antioxidant effect of the extract under the condition is significant.

The invention discloses a polypeptide with antioxidant activity and application thereof, and belongs to the technical field of biological medicine and fine chemical engineering. The amino acid sequence of the polypeptide is selected from QY, YG, YYYY, QPYY or WHYHDYKY. HPLC and MS structure confirmation shows that the synthesized polypeptide is high in purity and accurate in structure. In-vitro chemical experiments prove that the polypeptide (especially WHYHDYKY) has extremely high ABTS and DPPH free radical scavenging capacity, and the activity of the polypeptide is superior to or equal to that of glutathione (GSH). Cell experiments show that part of polypeptides (such as QY, YG, YYYY and QPYY) can significantly improve the survival rate of HepG2 cells under an oxidative damage model, and have a significant cell protection function. The polypeptide can be applied to the fields of antioxidant drugs, functional food, cosmetics, industrial antioxidants and the like according to the characteristics of the polypeptide.

The invention relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases), and particularly relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases). The invention relates to an application of MASLD in a medicine, and belongs to the technical field of biological medicines. In an in-vivo experiment, a mouse MASLD model is established by adopting methionine choline deficiency diet induction, and the treatment effect of cepharanthine on MASLD is researched. Experimental results show that the cepharanthine can significantly reduce the levels of triglyceride, glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other indexes of MASLD mice; a pathological detection result shows that cepharanthine can effectively reduce liver lipid deposition and inflammatory infiltration. In-vitro experiments prove that cepharanthine can effectively reduce the content of free fatty acid (Free Fatty Acid); fFA (Fatty Acid) induced HepG2 (HepG2) cell lipid accumulation and lipopolysaccharides (lipopolysaccharides) induced HepG2 cell lipid accumulation and lipopolysaccharides (FFA) induced HepG2 cell lipid accumulation; the THP-1 cell inflammatory response is induced by LPS (Lipopolysaccharide). In conclusion, the cepharanthine shows remarkable anti-lipid accumulation and anti-inflammatory effects in in-vivo and in-vitro experiments, can be used for preparing the medicine for preventing or treating MASLD, and has a wide application prospect.

The application discloses an alcoholic liver injury cell model and a construction method and application thereof, and belongs to the technical field of cell models. The technical problem to be solved is to improve the stability and accuracy of the constructed alcoholic liver injury cell model. The technical solution is a construction method of an alcoholic liver injury cell model, which comprises the following steps: after HepG2 cells are digested, the cells are resuspended and diluted by using DMEM complete culture medium, the cell liquid obtained after dilution is inoculated into a hole plate, alcohol solution is added after a certain time, and a sealing plate film is added at the same time, and then incubation is continued, and the alcoholic liver injury cell model is obtained.

The application discloses strigasiaticaside A and an extraction method and application thereof, and finds, through chemical component research on the whole grass of striga asiatica, a new synbinaphthyl tetrahydrofuran lignan glycoside, that is, strigasiaticaside A, identifies the chemical structure of the new compound through nuclear magnetic resonance, mass spectrometry, ultraviolet, infrared and circular dichroism spectrum technology.The structure of the new compound is identified as (-) sesamin-5-O-beta-D-glucopyranoside.The anti-hepatitis activity of the new natural product is evaluated by using LPS stimulated HepG2 cells.The results show that when the concentration is 100 muM, the compound has a significant inhibitory effect on the production of inflammatory factors IL-10 and NF-kappa B protein, and has no cytotoxicity, indicating that the compound may have potential anti-hepatitis activity.

The invention provides a TB derivative with photodynamic antibacterial and anti-tumor activity and a synthesis method thereof, the derivative comprises a carbazole-TB-thiophene-pyridinium derivative, the structural formula of the derivative is shown in the specification, and the four derivatives have good viscosity response and aggregation-induced emission property and can efficiently and synchronously generate I-type and II-type active oxygen. The TB-CB-1, the TB-TPA-1 and the TB-TPA-2 have good photodynamic antibacterial activity on tested gram positive bacteria (G + bacteria), and the antibacterial rates of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 on the three kinds of G + bacteria are all larger than 90% when the concentration of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 is 2 mol. L <-1 >. The four compounds have strong photodynamic anti-tumor activity and large light and dark toxicity difference, the IC50 values of the TB-CB-1 to MCF-7, A549 and HepG2 cells are all greater than 100 [mu] g.mL <-1 > in the absence of illumination, and the IC50 values are respectively reduced to 1.53 [mu] g.mL <-1 > and 0.28 [mu] g.mL <-1 > under illumination; the IC50 of the TB-TPA-2 to A549 cells under a dark condition is greater than 200 [mu] g.mL <-1 >, and the illumination is reduced to 2.01 [mu] g.mL <-1 >. The invention provides a new thought for design and synthesis of a novel photodynamic antibacterial / antitumor photosensitizer.

The present application provides a kind of pharmaceutical composition with lipid-lowering effect, including luteolin, isorhamnetin, 9-hydroxy-4,7-megastigme-3-ketone, lotus leaf base, 3-O-feruloyl quinic acid, kaempferol-3-O-acacia disaccharide-7-O-glucoside, kaempferol-3-O-beta-D-acacia glycoside and ginsenoside Rg1.The composition of example 1 has lipid-lowering efficacy verified by golden hamster hyperlipidemia model and AML12, HepG2 cell fatty degeneration model, the regulation effect of the composition of example 1 on the key target points of AMPK signal pathway and NF-κB signal pathway is verified by using molecular pharmacology experiment, and the mechanism of the composition of example 1 in treating hyperlipidemia by regulating energy metabolism and anti-inflammatory mechanism is described.

The invention belongs to the technical field of food, and relates to a honeysuckle-spirulina compound composition and a preparation method thereof, which can be applied to preparation of hangover alleviating health care products, functional beverages or pharmaceutical compositions for adjuvant therapy of alcoholic liver injury. The preparation method comprises the following steps: (1) weighing honeysuckle powder, adding 15-25 times volume of distilled water into 1-10 parts of honeysuckle powder, stirring and extracting for 160-200 minutes in a water bath at 70-80 DEG C in a dark place, and carrying out solid-liquid separation to obtain a honeysuckle extracting solution; (2) weighing 5-20 parts of spirulina platensis powder, and preparing a spirulina platensis extraction solution according to the method in the step (1); (3) mixing the obtained honeysuckle flower extracting solution with the spirulina platensis extracting solution; wherein the matching effect of 5 parts of honeysuckle flower powder and 10 parts of spirulina powder is optimal. The compound composition can solve the problem that the honeysuckle water extract is unstable, the stability index (TSI) within 6 hours is obviously lower than that of a single raw material group, and the total phenol retention rate is higher after the gastrointestinal environment is simulated; the natural anti-alcoholism liver-protecting food has the advantages that the anti-alcoholism liver-protecting food has a synergistic anti-alcoholism liver-protecting effect, the survival rate of HepG2 cells damaged by alcohol is obviously increased, the activities of ethanol dehydrogenase and acetaldehyde dehydrogenase are improved, the activities of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase are reduced, meanwhile, the scavenging rates of DPPH, ABTS and hydroxyl radicals are excellent, and a new direction is provided for development of natural anti-alcoholism liver-protecting food.

The application discloses a kind of polypeptide with antioxidant activity and application thereof, belong to biological medicine and fine chemical technology field.The amino acid sequence of the polypeptide is selected from QY, YG, YYYY, QPYY or WHYHDYKY.HPLC and MS structure confirmation, synthetic polypeptide is high in purity, accurate in structure.In vitro chemical experiment confirms that the polypeptide (especially WHYHDYKY) has very strong ABTS and DPPH free radical scavenging capacity, and the activity is better than or equivalent to glutathione (GSH).Cell experiment shows that part of polypeptide (such as QY, YG, YYYY, QPYY) can significantly improve the survival rate of HepG2 cell under oxidative damage model, and has significant cell protection function.The polypeptide of the application can be applied in the field of antioxidant drugs, functional food, cosmetics and industrial antioxidants, etc.

This invention discloses a carboxylesterase-activated mitochondrial-targeting fluorescent probe with photodynamic therapy properties, its preparation method, and its uses. The structure of the mitochondrial-targeting fluorescent probe is shown below. The mitochondrial-targeting fluorescent probe CML of this invention can specifically respond to different concentrations of carboxylesterases (CEs), with a detection limit as low as 0.30 U / L. Simultaneously, this probe can specifically target mitochondria, and through structural optimization (replacing the methyl group on the indole salt with a butyl group), its mitochondrial anchoring ability is significantly superior to that of methyl-substituted derivatives. Cytotoxicity experiments confirmed that the probe has good biocompatibility; confocal fluorescence imaging experiments showed that this probe can effectively monitor the fluorescence changes of endogenous and exogenous CEs in HepG2 cells. Most importantly, after being specifically activated by carboxylesterases, the probe can efficiently generate reactive oxygen species under light conditions, thereby exerting a photodynamic therapeutic effect on cancer cells.

This invention specifically discloses a novel chalcone compound, its preparation method, pharmaceutical composition, and applications. Experimental results show that this compound exhibits significant anti-inflammatory activity in a lipopolysaccharide-stimulated RAW 264.7 cell model, significantly superior to the positive control drug dexamethasone; and in a free fatty acid-treated HepG2 cell model, it exhibits significant inhibition of lipid accumulation, significantly superior to the positive control drug obeticholic acid. It can be used to develop drugs for the treatment of non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis, and related cirrhosis.

The invention discloses application of DDA1 and DULLARD in preparation of an anti-MASLD-HCC diagnosis and treatment reagent, and belongs to the technical field of diagnosis and treatment reagents. The expression levels of the DDA1 and the DULLARD in liver tissues of healthy and liver cancer patients are remarkably different, the influence of the expression quantity on the survival time of the liver cancer patients is remarkable, the influence of knocking down the expression of the DDA1 or DULLARD gene alone in HepG2 cells is small, and the proliferation of the HepG2 cells can be remarkably reduced by knocking down the DDA1 or DULLARD together. Therefore, the expression levels of the DDA1 and the DULLARD are related to the MASLD-HCC pathogenesis, and the DDA1 and the DULLARD can be used as diagnosis and treatment targets of the MASLD-HCC and have important application prospects in diagnosis, treatment and prognosis judgment of the MASLD-HCC and screening of anti-MASLD-HCC drugs.

The application discloses a tetrahedral framework nucleic acid complex loaded with equol and application of the complex in preparation of a medicine for relieving fatty liver disease. The complex is obtained by stable combination of tetrahedral framework nucleic acid and equol through hydrogen bond and hydrophobic interaction; the equol is loaded on the tetrahedral framework nucleic acid structure, and can be slowly released, so that the bioavailability of the equol is improved, and the problems of poor water solubility and low stability of the equol are effectively overcome. Meanwhile, the complex can inhibit lipid accumulation in HepG2 cells, relieve lipid deposition of liver cells, and reduce accumulation of TG and T-CHO in cells, and can be used for relieving fatty liver, and preparing more and more efficient fatty liver treatment medicines, and has wide application potential in intervention of lipid metabolism disorder and related metabolic diseases.

The invention relates to an alpha-glucosidase inhibitor and application thereof. The alpha-glucosidase inhibitor is vitamin C, dehydrogenated vitamin C, and 2, 3-diketone-L-gulonic acid. The influence of vitamin C, dehydrovitamin C and 2, 3-diketone-L-gulonic acid on alpha-glucosidase and HepG2 cell glucose consumption is researched through an in-vitro model, and the result shows that the vitamin C, dehydrovitamin C and 2, 3-diketone-L-gulonic acid can remarkably inhibit the activity of alpha-glucosidase and promote uptake and utilization of glucose by cells, so that the effect of improving insulin resistance is achieved.

Compositions containing cannabinoids and kinase inhibitors are useful for the treatment of hepatocellular carcinoma (HCC). Compositions containing cannabinolic acid (CBNA) and sorafenib act synergistically on HepG2 cells, an in vitro liver cancer model, and on ex vivo patient-derived xenograft (PDX) HCC models. The effects of all of the disclosed compositions are superior to sorafenib alone, which is the first- and second-line chemotherapeutic agent for the treatment of HCC.

The application discloses a nano vesicle containing quercetin and capable of protecting alcoholic liver injury, and a preparation and application thereof. Quercetin is an active component with antioxidant and anti-inflammatory effects contained in gold potted orchid, however, its in-vivo curative effect is reduced due to its low water solubility and bioavailability, and its clinical curative effect is limited. The method for obtaining quercetin by separating gold potted orchid-derived nano vesicles has the advantages of simple operation, rapidness and the like, and the lipid bilayer of the exosome-like vesicle can maintain the stability of quercetin for a long time as a natural protective film of quercetin. When acting on HepG2 cells, the gold potted orchid-derived nano vesicle can reasonably regulate the liver index of mice, effectively prevent or inhibit adverse reactions such as hepatocyte edema, fatty degeneration and lipid droplet accumulation caused by alcohol intake of the model, and has a significant curative effect on alcoholic liver disease.

The invention discloses an application of cypress hydrolat in preparation of antitumor drugs. The tumors comprise liver cancer, gastric cancer, lung cancer, cervical cancer, prostatic cancer and / or bladder cancer. Experiments show that the cypress hydrolat has an obvious inhibition effect on proliferation of gastric cancer SGC-7901, lung cancer A549, cervical cancer Hela, liver cancer Bel-7402 and HepG2, prostatic cancer PC-3 and bladder cancer EJ cells, can inhibit migration of two human liver cancer Bel-7402 and HepG2 cells, can prolong life of ascites tumor mice and inhibit growth of tumors, and can be used for preparing the cypress hydrolat. The cypress hydrolat has antineoplastic activity and antineoplastic effect, has the patent medicine potential of preparing medicine preparations for preventing or treating tumors, and can be used for developing and preparing antineoplastic medicines. The invention provides a new drug source for treating and curing liver cancer, gastric cancer, lung cancer, cervical cancer, prostatic cancer and bladder cancer, and provides a certain experimental basis for clinical application of the cypress hydrolat and development of new antitumor drugs.

The invention provides a coumarin-TB-pyridinium derivative as well as a synthesis method and application thereof, 4-bromoaniline, 4-bromo-3-methoxyaniline, paraformaldehyde, pyridine-4-boric acid, 4-(diethylamino) salicylaldehyde and the like are selected as raw materials, and compounds TB-CM-1 and TB-CM-2 are synthesized through a multi-step reaction, so that the coumarin-TB-pyridinium derivative is obtained. The structure is as follows: the compounds TB-CM-1 and TB-CM-2 both have excellent photophysical properties, viscosity response, aggregation-induced emission characteristics and good biocompatibility, can efficiently generate type I active oxygen, and have good application prospects in an anoxic environment. The TB-CM-2 also has photodynamic antibacterial activity on a staphylococcus aureus biological membrane. The two compounds have strong photodynamic anti-tumor activity and large difference of light toxicity and dark toxicity, wherein the IC50 of the TB-CM-2 on three tested tumor cells is greater than 100 [mu] g.mL <-1 > in the absence of illumination, and the IC50 of the TB-CM-2 on MCF-7, A549 and HepG2 cells is respectively reduced to 0.40 [mu] g.mL <-1 >, 0.13 [mu] g.mL <-1 > and 1.58 ng.mL <-1 > under illumination. The invention provides a new thought for design and synthesis of a novel efficient photodynamic antibacterial / antitumor photosensitizer.

The invention provides application of vitamin K2 in biphasic regulation of ER-alpha36 expression and hepatoma carcinoma cell growth, and belongs to the technical field of medicines.The vitamin K2 has an estrogen-like effect and can biphasic regulate hepatoma carcinoma cell growth through an ER-alpha36 signal transduction pathway, that is, low-dose vitamin K2 up-regulates ER-alpha36 expression and promotes HepG2 cell growth, so that the hepatoma carcinoma cell growth is promoted. A high dose of vitamin K2 down-regulates the expression of ER-alpha 36 and inhibits the growth of HepG2 cells. The new application of the vitamin K2 is found for the first time, and a new strategy is provided for treatment of hepatocellular carcinoma and drug development.

This invention provides a Ganoderma lucidum oligopeptide with anti-tumor effects and its preparation method. The Ganoderma lucidum oligopeptide with anti-tumor effects provided by this invention is an LC-R polypeptide. This polypeptide exhibits a high apoptosis rate in HepG2 cells and can effectively promote the increase of caspase-3 activity, thereby promoting cell apoptosis. Animal experiments have confirmed that this polypeptide can effectively inhibit tumor growth and has broad application prospects.